ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 648

Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus: Incidence Over a Ten Year Period

D. D. Gladman1, Dominique Ibanez2, Murray B. Urowitz2 and SLICC3, 1Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Division of Rheumatology Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: A large multicentre multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. The purpose of this study was to determine the incidence of vascular events during a 10 year follow-up and their attribution to AS.
Methods: An inception cohort of SLE patients from 31 centres from 12 countries has been assembled according to a standardized protocol between 2000 and 2012 to study risk factors for atherosclerosis. Patients enter the cohort within 15 months of SLE diagnosis (≥4 ACR criteria). Clinical and laboratory features of SLE and comorbidities are gathered in a standardized protocol at yearly intervals. Vascular events (VE) are described and attributed to SLE and AS on a specialized form. Events recorded include myocardial infarction (MI), angina, congestive heart failure (CHF), intermittent claudication (PVD), stroke, transient ischemic attack (TIA). Diagnosis of an event was confirmed using standard clinical criteria, relevant laboratory data and imaging where appropriate. Attribution to AS was made on the basis of lupus disease being inactive at the time of the event, and/or the presence of typical AS changes on imaging or pathology and/or evidence of AS elsewhere. The incidence of VE was calculated over the 10 years for all VE occurring after diagnosis, and then for atherosclerotic VE  (AVE). Kaplan-Meier curves were used  to estimate the cumulative incidence rates since SLE diagnosis

Results: Since 2000 1844 patients have been entered into the cohort (88.9%F, age at SLE 34.7y). Caucasian 49.2%, Black 16.5%, Asian 14.9%, Hispanic 15.3%, other 4.1%.  Thus far there have been 157 VE in 115 patients after the diagnosis of SLE. These include: MI (14), angina (26), CHF (36), PVD (11), TIA (27), stroke (38), pacemaker insertion (5). 64 of the events were attributed to active lupus and 44 to other causes or missing. 49 events in 37 patients were attributed to AS including: MI (8), angina (19), CHF (6), PVD (6), TIA (5), pacemaker (3), stroke (2).

Table cumulative incidence of 1st vascular events since diagnosis of SLE

Years since SLE Dx

Number

VE

N=115

AVE

N=37

0

1844

0.2%

0.1%

1

1479

3.0%

0.7%

2

1305

4.0%

0.9%

3

1097

5.4%

1.4%

4

948

6.2%

1.9%

5

768

7.3%

2.4%

6

600

7.7%

2.5%

7

459

8.9%

2.9%

8

342

9.4%

3.2%

9

233

10.1%

3.9%

10

138

11.2%

4.4%

 

Conclusion : Over the follow-up of an inception cohort with SLE there were 157 vascular events of which 49 were attributable to AS.  The incidence of AVE increased by 0.5% per year reaching a total of 4.4% at 10 years.


Disclosure:

D. D. Gladman,
None;

D. Ibanez,
None;

M. B. Urowitz,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/atherosclerotic-vascular-events-in-a-multinational-inception-cohort-of-systemic-lupus-erythematosus-incidence-over-a-ten-year-period/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology